Disruption of LINC01232/E2F2/NBR1/MHC‐I by shRNA or blocking the corresponding antibodies largely diminished the tumor‐supportive effects of LINC01232 and suppressed tumor growth driven by M2‐type macrophages. Here, LINC01232 is linked to neoplasm.